...
首页> 外文期刊>European review for medical and pharmacological sciences. >MicroRNA-330-5p promotes the development of osteosarcoma by regulating SPRY2
【24h】

MicroRNA-330-5p promotes the development of osteosarcoma by regulating SPRY2

机译:MicroRNA-330-5P通过调节SPRy2促进骨肉瘤的发育

获取原文
           

摘要

OBJECTIVE: MicroRNA is an endogenous, non-coding small RNA that has a significant role in regulating organisms and pathology. Previous studies have demonstrated that microRNA-330-5p was a cancer-promoting gene. However, the role of microRNA-330-5p in osteosarcoma (OS) has not been reported. The aim of this work was to explore the characteristics of microRNA-330-5p expression in OS, and to further study its expression in OS and its relationship with clinicopathological parameters and prognosis. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed to investigate the expression of microRNA-330-5p in 48 pairs of OS tissues and paracancer tissues, and to analyze the relationship between the expression of microRNA-330-5p and OS clinical indicators and patient prognosis. Meanwhile, qRT-PCR was performed to verify the microRNA-330-5p expression in OS cells. In addition, the microRNA-330-5p knockdown expression model was constructed using lentivirus in OS cell lines U2OS and MG63. The effects of microRNA-330-5p on the biological function of OS cells were analyzed by Cell Counting Kit-8 (CCK-8) and transwell experiments. The potential mechanism was explored by Western blot. RESULTS: In this paper, qRT-PCR results showed that the expression of microRNA-330-5p in OS was higher than that in paracancer tissues, and the difference was statistically significant. Compared with microRNA-330-5p low expression group, patients with high expression of microRNA -330-5p had a higher prevalence of distant metastasis and a lower overall survival rate. In vitro experiment showed that the proliferation, invasion and metastasis abilities of the cells in the microRNA-330-5p silencing group were markedly decreased compared with the negative control group (NC group). Western blot results demonstrated that microRNA-330-5p inhibitor can activate SPRY2 and regulate the expression of key proteins, such as p-Smad2, p-Smad3, TGF-β1, MMP9 and Vimentin in the TGF-β1/Smad signaling pathway. It was found that there was a mutual regulation between microRNA-330-5p and SPRY2, which promoted the malignant progression of OS. CONCLUSIONS: The expression of microRNA-330-5p was markedly increased in OS, which was associated with distant metastasis and poor prognosis. Furthermore, we found that microRNA-330-5p may promote the vicious progression of OS by inter-modulating SPRY2 and the TGF-β1/Smad signaling pathways.
机译:目的:MicroRNA是内源性,非编码的小RNA,具有在调节生物和病理学方面具有重要作用。以前的研究表明,microRNA-330-5P是癌症促进基因。然而,尚未报道MicroRNA-330-5P在骨肉瘤(OS)中的作用。这项工作的目的是探讨OS中MicroRNA-330-5P表达的特征,进一步研究其在OS中的表达及其与临床病理参数和预后的关系。患者和方法:进行定量实时 - 聚合酶链反应(QRT-PCR)以研究MicroRNA-330-5P在48对OS组织和副癌组织中的表达,并分析MicroRNA-330表达之间的关系-5P和OS临床指标和患者预后。同时,进行QRT-PCR以验证OS细胞中的MicroRNA-330-5P表达。此外,MicroRNA-330-5P敲低表达式模型在OS细胞系U2OS和MG63中使用Lentivirus构建。通过细胞计数试剂盒-8(CCK-8)和Transwell实验分析MicroRNA-330-5P对OS细胞生物功能的影响。潜在机制是通过Western印迹探索的。结果:在本文中,QRT-PCR结果表明,OS中的MicroRNA-330-5P的表达高于Paracancer组织中的表达,差异是统计学意义。与MicroRNA-330-5P低表达组相比,MicroRNA -330-5P高表达的患者具有更高的远端转移率和整体存活率较低。体外实验表明,与阴性对照组(NC组)相比,MicroRNA-330-5P沉默组细胞的增殖,侵袭和转移能力明显降低。 Western印迹结果表明,MicroRNA-330-5P抑制剂可以激活SPry2并调节关键蛋白的表达,例如P-Smad2,P-Smad3,TGF-β1,MMP9和Vimentin在TGF-β1/ Smad信号通路中。发现MicroRNA-330-5P和SPRY2之间的相互调节,促进了OS的恶性进展。结论:OS中microRNA-330-5P的表达显着增加,与远处转移和预后差有关。此外,我们发现MicroRNA-330-5P可以通过调制间的SPRy2和TGF-β1/ Smad信号传导途径来促进OS的恶性进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号